Mydecine Innovations Financials
| MYCOF Stock | USD 0.01 0 25.00% |
Mydecine |
Mydecine Innovations Stock Summary
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | CA62849F1018 |
| Business Address | 789 West Pender |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.mydecine.com |
| Phone | 720 277 9879 |
| Currency | USD - US Dollar |
Mydecine Innovations Key Financial Ratios
There are many critical financial ratios that Mydecine Innovations' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Mydecine Innovations reports annually and quarterly.| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Target Price | 140.0 | |||
| Number Of Employees | 11 | |||
| Beta | 3.42 |
Mydecine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mydecine Innovations's current stock value. Our valuation model uses many indicators to compare Mydecine Innovations value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mydecine Innovations competition to find correlations between indicators driving Mydecine Innovations's intrinsic value. More Info.Mydecine Innovations Group is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mydecine Innovations' earnings, one of the primary drivers of an investment's value.Mydecine Innovations Systematic Risk
Mydecine Innovations' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mydecine Innovations volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Mydecine Innovations correlated with the market. If Beta is less than 0 Mydecine Innovations generally moves in the opposite direction as compared to the market. If Mydecine Innovations Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mydecine Innovations is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mydecine Innovations is generally in the same direction as the market. If Beta > 1 Mydecine Innovations moves generally in the same direction as, but more than the movement of the benchmark.
Mydecine Innovations December 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mydecine Innovations help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mydecine Innovations Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mydecine Innovations Group based on widely used predictive technical indicators. In general, we focus on analyzing Mydecine Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mydecine Innovations's daily price indicators and compare them against related drivers.
| Downside Deviation | 33.07 | |||
| Information Ratio | 0.1265 | |||
| Maximum Drawdown | 180.56 | |||
| Value At Risk | (37.50) | |||
| Potential Upside | 55.56 |
Complementary Tools for Mydecine Pink Sheet analysis
When running Mydecine Innovations' price analysis, check to measure Mydecine Innovations' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mydecine Innovations is operating at the current time. Most of Mydecine Innovations' value examination focuses on studying past and present price action to predict the probability of Mydecine Innovations' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mydecine Innovations' price. Additionally, you may evaluate how the addition of Mydecine Innovations to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |